I don't see how it could possibly be bad. At worst, it's irrelevant. I think the poster said he had friends working at AMGEN. If they just took a quick look at USRM as a favor to a friend and made a basic assessment, it might be irrelevant. On the other hand, if they did this because they see USRM as a threat or an opportunity, I think it could be very good news.
I agree with other buyers that USRM would be a great buyout target. It's a tiny company with big potential. Some competitors probably see USRM as a chance to expand their existing business. Others might view a buyout as a cheap way to eliminate a threat to their drug revenue. I'd prefer the first type of buyout because I'd hate to see stem cell treatments and equipment patents being purchased and hidden from patients who could benefit. Just my thoughts.
News 
Market Data 
Discover 
AI
